2021
Surgical strategies for older patients with glioblastoma
Barak T, Vetsa S, Nadar A, Jin L, Gupte TP, Fomchenko EI, Miyagishima DF, Yalcin K, Vasandani S, Gorelick E, Zhao AY, Antonios J, Theriault BC, Lifton N, Marianayagam N, Omay B, Omay ZE, Huttner A, McGuone D, Blondin NA, Corbin Z, Fulbright RK, Moliterno J. Surgical strategies for older patients with glioblastoma. Journal Of Neuro-Oncology 2021, 155: 255-264. PMID: 34626296, PMCID: PMC8651607, DOI: 10.1007/s11060-021-03862-z.Peer-Reviewed Original ResearchConceptsKarnofsky performance scoreLength of surgeryOlder patientsOverall survivalPostoperative complicationsSurgical resectionSurgical strategyLow preoperative KPS scorePoor Karnofsky performance scoreLow Karnofsky performance scoreYale-New Haven HospitalPostoperative adjuvant treatmentPreoperative KPS scoreAdjuvant treatment regimensExtent of resectionNew Haven HospitalUse of ioMRIAdjuvant treatmentHospital stayKPS scoreMethodsClinical dataConsecutive patientsPrognostic factorsTreatment regimensExperienced hands
2003
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal Of Clinical Oncology 2003, 21: 1431-9. PMID: 12668651, DOI: 10.1200/jco.2003.09.081.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Administration ScheduleFemaleFilgrastimGranulocyte Colony-Stimulating FactorHumansMiddle AgedMultivariate AnalysisPaclitaxelProportional Hazards ModelsRecombinant ProteinsSurvival AnalysisTreatment OutcomeConceptsOverall survivalDose-dense regimensBreast cancerAxillary node-positive breast cancerNode-positive primary breast cancerNode-positive breast cancerConcurrent combination chemotherapyDose-dense treatmentProtocol-specified analysisPostoperative adjuvant treatmentPrimary end pointPrimary breast cancerDose densityAdjuvant chemotherapyConcurrent chemotherapyAdjuvant treatmentSequential chemotherapySevere neutropeniaCombination chemotherapyClinical outcomesFemale patientsTreatment failureSequential doxorubicinConcurrent doxorubicinChemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply